Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium breve A1
- Development stage
- Unknown
- Lead developer
- Morinaga Milk Industry
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium breve A1 (also known as MCC1274) is a proprietary probiotic bacterial strain developed by Morinaga Milk Industry. Originally isolated from the intestinal tract of an infant, it is being developed as a live biotherapeutic product (LBP) for neurological and psychiatric conditions via the gut-brain axis. The strain has demonstrated the ability to suppress hippocampal inflammation and immune-reactive gene expression induced by amyloid-beta (Aβ). In preclinical models, it has been shown to restore hippocampal synaptic plasticity by regulating the expression of neuropsin (KLK8), postsynaptic density protein-95 (PSD-95), and synaptophysin. Clinical development is primarily focused on Mild Cognitive Impairment (MCI) and Alzheimer's disease, where it has reached Phase 2 trials in the U.S. and shown potential improvements in memory and visuospatial function. It is also being investigated for autism spectrum disorder (ASD), schizophrenia-related anxiety and depression, and Parkinson's disease.
- Brand names
- Memory Bifidobacterium
- Other names
- Bifidobacterium breve strain A1B. breve A1Bifidobacterium MCC1274
02
Targets
Aβ (Amyloid-beta peptides and aggregates)DLG4 (Disks Large Homolog 4)
Beyond the preview
Go deeper on bifidobacterium breve A1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium breve A1.